I don’t think it’s a slam dunk.” Johnson said her enthusiasm about SC PD-1/PD-L1 inhibitors is tempered after speaking with the pharmacist at her practice, SCRI Oncology Partners.

Safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of HLX301, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.

There are few PK/PD studies available with aztreonam, but in a murine thigh infection model with human simulated doses, 2 g aztreonam every 6 h over 30 min was able to reach a f T>MIC of 100, 90 ...

The pharmacist helps translate a lot of scientific and clinical information. The more pharmacists understand about how drugs are handled by the body (PK) and how they control their effects (PD), the ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...

Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors.

Carbapenems were commonly prescribed as targeted therapy for extended-spectrum cephalosporin-resistant Enterobacterales infections despite significant changes in guidance, data show.

Broad spectrum carbapenems were the most commonly used therapy for targeted treatment of extended-spectrum cephalosporin-resistant (ECR) Enterobacterales infections in U.S. hospitals, according to ...

Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting - AAPM is the primary organization for pain medicine physicians in the U.S.

Polpharma Biologics announced topline results demonstrating the pharmacokinetic and pharmacodynamics comparability of its biosimilar candidate PB016 to its reference drug, Entyvio®*.